HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

Last updated: June 25, 2026
Sponsor: HighField Biopharmaceuticals Corporation
Overall Status: Active - Recruiting

Phase

1

Condition

Neoplasms

Treatment

HF158K1 / 1.4 g lipid dose

HF158K1 /Arm 60 mg/m²

HF158K1 / 2.2 g lipid dose

Clinical Study ID

NCT05861895
HF158K1-101
  • Ages 18-75
  • All Genders

Study Summary

HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Voluntary to participate and sign ICF.

  2. Age ≥ 18 and ≤ 75 years.

  3. Unresectable or metastatic advanced solid tumors with HER-2 expression (IHC 3+, 2+,or 1+).

  4. ECOG score 0-1.

  5. Expected survival ≥ 6 months.

  6. At least one measurable lesion per RECIST v1.1.

  7. Adequate organ function: ANC ≥ 1.5×10⁹/L, LYM ≥ 1.0×10⁹/L, PLT ≥ 90×10⁹/L, HGB ≥ 8.0g/dL; APTT ≤ 1.5×ULN, INR ≤ 1.5; TBIL ≤ 1.5×ULN, ALT/AST ≤ 2.5×ULN (≤ 5×ULN if livermetastases); CrCl ≥ 30 mL/min; LVEF ≥ 50%.

  8. Agreement to use effective contraception.

Exclusion

Exclusion Criteria:

  1. Cumulative doxorubicin dose ≥ 350 mg/m² or prior anthracycline-inducedcardiotoxicity.

  2. Current use of immunosuppressants or systemic corticosteroids (> 10 mg/dayprednisone).

  3. Prior anti-tumor therapy < 2 weeks (4 weeks for nitrosourea/mitomycin C).

  4. Symptomatic CNS metastases.

  5. Unresolved AEs from prior therapy > Grade 1.

  6. Serious cardiovascular diseases (thromboembolic events within 3 months, NYHA III-IV,ACS within 6 months, or uncontrolled hypertension).

  7. Active infection or unexplained fever > 38.5°C.

  8. HIV, active HBV or HCV.

  9. Pregnant or breastfeeding.

Study Design

Total Participants: 84
Treatment Group(s): 9
Primary Treatment: HF158K1 / 1.4 g lipid dose
Phase: 1
Study Start date:
December 12, 2023
Estimated Completion Date:
December 23, 2027

Study Description

This study is a multi-regional, open-label, multiple-dose administration dose-escalation and dose-expansion study, including a Dose-Escalation Phase (Ia) and a Dose-Expansion Phase (Ib).

HF158K1 contains multiple copies of the targeting antibody on liposome surface. It is designed to bind and deliver the chemotherapeutic doxorubicin to tumor cells at even very low HER2 expression levels. The study recruits patients with unresectable or metastatic advanced solid tumors (HER-2 positive (IHC 3+, or IHC 2+ with ISH +) or HER-2 low expression (IHC 2+ with ISH -, or IHC 1+)) who have failed or are intolerant (disease progression, or intolerance to chemotherapy, targeted therapy, etc.) to standard treatment, or currently have no available treatment regimen.

Phase 1a(Dose escalation) will assess the safety，tolerability，pharmacokinetics of HF158K1 in participants to determine the maximum tolerated dose (MTD) of HF158K1 through the incidence of dose-limiting toxicity (DLT).

Phase 1b (Dose bridging) will be conducted in Chinese patients to bridge the safety and pharmacokinetic data between different ethnic populations.

Phase 1c(Dose expansion) will assess safety and preliminary efficacy of HF158K1 in participants with specific tumor types in selected dose groups.

Connect with a study center

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong 510060
    China

    Active - Recruiting

  • Zhejiang Xiaoshan Hospital

    Hangzhou, Zhejiang
    China

    Site Not Available

  • Mary Crowley Cancer Research

    Dallas, Texas 75241
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.